PT - JOURNAL ARTICLE AU - Marzia Lazzerini AU - Idanna Sforzi AU - Sandra Trapani AU - Paolo Biban AU - Davide Silvagni AU - Ilaria Mariani AU - Giovanna Villa AU - Jessica Tibaldi AU - Luca Bertacca AU - Enrico Felici AU - Giuseppina Perricone AU - Roberta Parrino AU - Claudia Gioè AU - Sara Lega AU - Mariasole Conte AU - Federico Marchetti AU - Annamaria Magista AU - Paola Berlese AU - Stefano Martelossi AU - Francesca Vaienti AU - Enrico Valletta AU - Margherita Mauro AU - Roberto Dall’Amico AU - Silvia Fasoli AU - Antonio Gatto AU - Antonio Chiaretti AU - Danica Dragovic AU - Paola Pascolo AU - Chiara Pilotto AU - Ilaria Liguoro AU - Elisabetta Miorin AU - Francesca Saretta AU - Gianluca Trobia AU - Antonella Di Stefano AU - Azzurra Orlandi AU - Fabio Cardinale AU - Riccardo Lubrano AU - Alessia Testa AU - Marco Binotti AU - Valentina Moressa AU - Egidio Barbi AU - Benedetta Armocida ED - , TI - Characteristics and risk factors for SARS-CoV-2 among children in Italy: a cross-sectional study in 20 pediatric centers AID - 10.1101/2021.03.17.21253610 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.17.21253610 4099 - http://medrxiv.org/content/early/2021/03/17/2021.03.17.21253610.short 4100 - http://medrxiv.org/content/early/2021/03/17/2021.03.17.21253610.full AB - Background No study has described factors associated with COVID-19 diagnosis in children.Aim Describe characteristics and risk factors for COVID-19 diagnosis in children tested in 20 pediatric centers across Italy.Methods Cases aged 0-18 years tested for SARS-CoV-2 between February 23 and May 24 2020 were included. Our primary analysis focused on children tested because of COVID-19 suggestive symptoms.Results Among 2494 children tested for SARS-CoV-2, 2148 (86.1%) had symptoms suggestive of COVID-19. Clinical presentation of SARS-CoV-2 included - beside fever (82.4%) and respiratory signs or symptoms (60.4%) – also gastrointestinal (18.2%), neurological (18.9%), cutaneous (3.8%) and other flu-like presentations (17.8%). In multivariate analysis, factors significantly associated with SARS-CoV-2 were: exposure history (adjusted OR 39.83 95%CI 17.52-90.55 p<0.0001), cardiac disease (adjusted OR 3.10 95%CI 1.19-5.02 p<0.0001), fever (adjusted OR 3.05 % 95% CI 1.67-5.58 p=0.0003), and anosmia/ageusia (OR 4.08 95%CI 1.69 −9.84 p=0.002). Among 190 (7.6%) children diagnosed with SARS-CoV-2, only four (2.1%) required respiratory support and two (1.1%) were admitted in ICU, while 100% recovered.Conclusion Recommendations for SARS-CoV-2 testing in children should be updated based on the evidence of broader clinical features. Exposure history, fever, and anosmia/ageusia are strong risk factors for COVID-19 in children, while other symptoms don’t seem helping discriminating in between the SARS-CoV-2 positive and the negative cases. This study confirm that COVID-19 is a mild disease in the general population of children in Italy. Further studies are needed to understand the risk, clinical spectrum and outcomes of COVID-19 in children with specific preexisting conditions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNon external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review Board of the Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy (reference number 01/2020 25.03.2020).Given the purely descriptive and retrospective nature of the study, informed consent was waived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.